In this study, we want to learn if modifying the region of your head and neck that receives the radiation therapy will affect your xerostomia (excessive dry mouth).

Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment.

The purpose of this study is to see how safe the investigational study drug is - either IGV-001 (study drug) plus standard of care (SOC) or placebo plus SOC - and to see if it works in slowing GBM tumor regrowth. SOC treatment for this study refers to temozolomide and radiotherapy used to treat your cancer.

Do you have untreated Acute Lymphoblastic Leukemia (ALL) and/or you have relapsed or refractory ALL? You may be able to take part in a research study to help us learn more about the effects of a combination of two drugs on your leukemia.

Do you have a new diagnosis of Acute Myeloid Leukemia and are looking for another treatment option? In this study, we are looking to see if the study drug (Tagraxofusp) can help control Leukemia or achieve remission.

Have you been diagnosed with unfavorable risk prostate cancer? Are you looking for treatment options? If so, you may be able to participate in a clinical trial examining different treatment options for prostate cancer.

Have you been recently diagnosed with follicular lymphoma (a type of non-Hodgkin lymphoma)? You may be able to take part in a research study to learn more about the safety and tolerability of an experimental drug called odronextamab.

Have you been diagnosed with locally advanced or metastatic hepatocellular carcinoma? If so, you may be a good fit to help us learn if adding tiragolumab to standard therapy could help you and others with your condition.

Do you have a pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma of the oral cavity? If so, you may be able to participate in a phase II/III research study to determine how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer.